HIFs as central regulators of gastric cancer pathogenesis

Cancer Biology and Therapy

Volumn 10, Issue 4, 2010, Pages 383-385

  Rohwer, Nadine ^a   Cramer, Thorsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Gastric cancer; HIF 1 ; HIF 2 ; Hypoxia; Invasion; Metastasis; Migration

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 2ALPHA; REACTIVE OXYGEN METABOLITE;

CELL CYCLE REGULATION; HUMAN; IMMUNOREACTIVITY; NOTE; STOMACH CANCER; STOMACH CARCINOGENESIS;

AGE FACTORS; ANIMALS; ARYL HYDROCARBON RECEPTOR NUCLEAR TRANSLOCATOR; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL HYPOXIA; GENE EXPRESSION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; NEOPLASM METASTASIS; PROGNOSIS; STOMACH NEOPLASMS; SURVIVAL RATE;

EID: 77957125732     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.10.4.12850     Document Type: Note

References (31)

1. Parkin DM. Global cancer statistics in the year 2000. The Lancet Oncology 2001; 2:533-43.
2. Hohenberger P, Gretschel S. Gastric cancer. Lancet 2003; 362:305-15.
3. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2:38-47.
4. Vaupel P, Mayer A, Hockel M. Tumor hypoxia and malignant progression. Methods Enzymol 2004; 381:335-54.
5. Weidemann A, Johnson RS. Biology of HIF-1alpha. Cell Death Differ 2008; 15:621-7.
6. 2 tension. Proc Natl Acad Sci USA 1995; 92:5510-4.
7. Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem 1995; 270:1230-7.
8. 2 sensing. Science 2001; 292:464-8.
9. 2-regulated prolyl hydroxylation. Science 2001; 292:468-72.
10. Maxwell PH, Wiesener MS, Chang GW, Clifford SC, Vaux EC, Cockman ME, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999; 399:271-5.
11. Ohh M, Park CW, Ivan M, Hoffman MA, Kim TY, Huang LE, et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat Cell Biol 2000; 2:423-7.
12. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3:177-85. (Pubitemid 43316523)
13. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab 2006; 3:187-97. (Pubitemid 43316524)
14. Semenza GL. Oxygen-dependent regulation of mitochondrial respiration by hypoxia-inducible factor 1. Biochem J 2007; 405:1-9.
15. Zhang H, Gao P, Fukuda R, Kumar G, Krishnamachary B, Zeller KI, et al. HIF-1 inhibits mitochondrial biogenesis and cellular respiration in VHL-deficient renal cell carcinoma by repression of C-MYC activity. Cancer Cell 2007; 11:407-20.
16. Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, Wesley JB, et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem 2008; 283:10892-903.
17. Rohwer N, Welzel M, Daskalow K, Pfander D, Wiedenmann B, Detjen K, et al. Hypoxia-inducible factor 1alpha mediates anoikis resistance via suppression of alpha5 integrin. Cancer Res 2008; 68:10113-20.
18. Talks KL, Turley H, Gatter KC, Maxwell PH, Pugh CW, Ratcliffe PJ, et al. The expression and distribution of the hypoxia-inducible factors HIF-1alpha and HIF-2alpha in normal human tissues, cancers and tumor-associated macrophages. Am J Pathol 2000; 157:411-21. (Pubitemid 30626905)
19. Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999; 59:5830-5.
20. Semenza GL. Hypoxia-inducible factor 1 (HIF-1) pathway. Sci STKE 2007; 2007:8.
21. Stoeltzing O, McCarty MF, Wey JS, Fan F, Liu W, Belcheva A, et al. Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis and vessel maturation. J Natl Cancer Inst 2004; 96:946-56.
22. Yeo EJ, Chun YS, Cho YS, Kim J, Lee JC, Kim MS, et al. YC-1: a potential anticancer drug targeting hypoxia-inducible factor 1. J Natl Cancer Inst 2003; 95:516-25. (Pubitemid 36511622)
23. Cabuk D, Basaran G, Celikel C, Dane F, Yumuk PF, Iyikesici MS, et al. Vascular endothelial growth factor, hypoxia-inducible factor 1alpha and CD34 expressions in early-stage gastric tumors: relationship with pathological factors and prognostic impact on survival. Oncology 2007; 72:111-7.
24. Griffiths EA, Pritchard SA, Valentine HR, Whitchelo N, Bishop PW, Ebert MP, et al. Hypoxia-inducible factor-1alpha expression in the gastric carcinogenesis sequence and its prognostic role in gastric and gastrooesophageal adenocarcinomas. Br J Cancer 2007; 96:95-103.
25. Mizokami K, Kakeji Y, Oda S, Irie K, Yonemura T, Konishi F, et al. Clinicopathologic significance of hypoxia-inducible factor 1alpha overexpression in gastric carcinomas. J Surg Oncol 2006; 94:149-54. (Pubitemid 44267197)
26. Rohwer N, Lobitz S, Daskalow K, Jons T, Vieth M, Schlag PM, et al. HIF-1alpha determines the metastatic potential of gastric cancer cells. Br J Cancer 2009; 100:772-81.
27. Sumiyoshi Y, Kakeji Y, Egashira A, Mizokami K, Orita H, Maehara Y. Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. Clin Cancer Res 2006; 12:5112-7. (Pubitemid 44453338)
28. Urano N, Fujiwara Y, Doki Y, Tsujie M, Yamamoto H, Miyata H, et al. Overexpression of hypoxia-inducible factor-1alpha in gastric adenocarcinoma. Gastric Cancer 2006; 9:44-9.
29. Griffiths EA, Pritchard SA, McGrath SM, Valentine HR, Price PM, Welch IM, et al. Hypoxia-associated markers in gastric carcinogenesis and HIF-2alpha in gastric and gastro-oesophageal cancer prognosis. Br J Cancer 2008; 98:965-73.
30. Wang Y, Li Z, Zhang H, Jin H, Sun L, Dong H, et al. HIF-1α and HIF-2α correlate with migration and invasion in gastric cancer. Cancer Biol Ther 2010; 10.
31. Nakamura J, Kitajima Y, Kai K, Mitsuno M, Ide T, Hashiguchi K, et al. Hypoxia-inducible factor-1alpha expression predicts the response to 5-fluorouracil-based adjuvant chemotherapy in advanced gastric cancer. Oncol Rep 2009; 22:693-9.